Bracket Acquires Clintara In Move To Strengthen Rater Training, Quality Assurance, And Electronic Clinical Outcomes Assessment Capabilities


Applied Clinical Trials


WAYNE, Pa. and BOSTON, June 22, 2015 /PRNewswire/ -- Bracket Global, LLC and Clintara are pleased to announce the two companies have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA). The integration will include Clintara's innovative C-VISA Subject Eligibility Validation program designed to ensure appropriate patients are enrolled in clinical trials.

Bracket CEO Jeff Kinell stated, "I am impressed by the culture, business practices, and scientific innovation reflected in Clintara's steady growth and impact on our industry. I am truly excited about our future opportunities together."

Founded in 2009 by Steven D. Targum, MD, Clintara's methodology and technology includes audio-digital pen recordings of site-based interviews and site-independent "dual" scoring reviews. The Clintara surveillance strategy has enhanced ratings precision and improved the data integrity of clinical trials. 

The Clintara leadership will assume expanded roles within Bracket. Dr. Targum will become the Scientific Director of Bracket and will work closely with Bracket's Senior Vice President and Chief Medical Officer, David Daniel, MD. Clintara CEO Colin Bower will become Vice President, Scientific Services and will work with the Bracket leadership team and Scientific Advisory Board to develop cutting-edge solutions to improve the conduct of clinical trials.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.